Results 111 to 120 of about 8,397 (218)

Experimental cutaneous leishmaniasis: transmission electron microscopy of the inoculation site

open access: yesInternational Journal of Experimental Pathology, 1997
Tissue response against inoculation of Leishmania (Leishmania) amazonensis promastigotes in the hind footpad was quite different between two strains of mice: in BALB/c animals there was parasitism of perineurial cells by the 8th week post inoculation (WPI) and heavy parasitism of macrophages, as well as degenerated extracellular parasites close to ...
C, Vasconcellos, M N, Sotto
openaire   +3 more sources

First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony.

open access: yesPLoS Neglected Tropical Diseases, 2009
BackgroundCurrent therapies for cutaneous leishmaniasis are limited by poor efficacy, long-term course of treatment, and the development of resistance.
Cesar Miranda-Verastegui   +8 more
doaj   +1 more source

Studies on the infectivity and pathogenecity of Leishmania species from Leishmaniasis diffusa and on the immune response of the host in laboratory animals [PDF]

open access: yes
1. The infectivity of three strains of Leishmania braziliensis pifanoi, strain V1 and V2 from Venezuela and L 15 from Brazil was studied in albino, hairless, "shaven" and "shaven" x albino mice; in hamsters, rats and guinea pigs. Rats and guinea-pigs
Hayatee, Zuhair
core   +1 more source

Evaluation of PCR as a diagnostic mass-screening tool to detect Leishmania (Viannia) spp. in domestic dogs (Canis familiaris) [PDF]

open access: yes, 2003
Several studies have suggested that the PCR could be used in epidemiological mass-screening surveys to detect Leishmania (Piannia) spp. infection in human and animal hosts.
Reithinger, Richard   +7 more
core   +1 more source

Improving reproducibility and translational potential of mouse models: lessons from studying leishmaniasis

open access: yesFrontiers in Immunology
Leishmaniasis is a complex disease caused by protozoan parasites of the genus Leishmania, which are transmitted by phlebotomine sand flies. The clinical manifestations of leishmaniasis are diverse, ranging from self-healing cutaneous lesions to fatal ...
Mahmoud Nateghi-Rostami   +5 more
doaj   +1 more source

Generation of luciferase-expressing Leishmania infantum chagasi and assessment of miltefosine efficacy in infected hamsters through bioimaging.

open access: yesPLoS Neglected Tropical Diseases, 2015
BackgroundThe only oral drug available for the treatment of leishmaniasis is miltefosine, described and approved for visceral leishmaniasis in India. Miltefosine is under evaluation for the treatment of cutaneous leishmaniasis in the Americas although ...
Juliana Q Reimão   +5 more
doaj   +1 more source

MPLA and AddaVax® Adjuvants Fail to Promote Intramuscular LaAg Vaccine Protectiveness against Experimental Cutaneous Leishmaniasis. [PDF]

open access: yesMicroorganisms, 2021
Oliveira-Maciel D   +10 more
europepmc   +1 more source

Drug-containing hydrophobic dressings as a topical experimental therapy for cutaneous leishmaniasis

open access: yesJournal of Parasitic Diseases, 2019
Cutaneous leishmaniasis (CL), a clinical condition caused mainly by Leishmania amazonensis in Brazil, is characterized by topical, painless ulcers. The current treatment, based on intravenous administration of pentavalent antimonials, presents low adherence by patients and may cause serious adverse effects, leading to the need for searching new ...
Viviane Pereira   +5 more
openaire   +3 more sources

Risk factors of visceral leishmaniasis in East Africa: a case-control study in Pokot territory of Kenya and Uganda [PDF]

open access: yes, 2007
BACKGROUND: In East Africa, visceral leishmaniasis (VL) is endemic in parts of Sudan, Ethiopia, Somalia, Kenya and Uganda. It is caused by Leishmania donovani and transmitted by the sandfly vector Phlebotomus martini.
Kolaczinski, Jan H   +27 more
core   +2 more sources

Home - About - Disclaimer - Privacy